Reuters logo
4 个月前
BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C
2017年4月28日 / 中午12点00分 / 4 个月前

BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C

April 28 (Reuters) - Bristol-myers Squibb Co

* China FDA approves country's first all-oral regimen for chronic Hepatitis C, daklinza (daclatasvir) in combination with sunvepra (asunaprevir)

* Bristol-Myers Squibb Co - daklinza also approved in China for use in combination with other agents, including sofosbuvir, for HCV genotypes 1-6

* Bristol-Myers Squibb Co - sofosbuvir is under review by China food and drug administration and is not currently licensed in China Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below